Aviragen Therapeutics to Present at Upcoming Investor Conferences
September 07 2016 - 9:00AM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, announced today that Aviragen's
CEO & President Joseph Patti, PhD will present a corporate
overview at the following upcoming conferences:
- Rodman & Renshaw 18th Annual Global Investment
Conference at 4:15 p.m. ET on Tuesday, September 13, 2016
in New York, NY.
Link: http://wsw.com/webcast/rrshq26/avir
- Ladenburg Thalmann 2016 Healthcare Conference
at 2:30 p.m. ET on Tuesday, September 27, 2016 in New York, NY.
Link: http://wsw.com/webcast/ladenburg2/avir
A live audio webcast of each presentation can be accessed under
“Events and Presentations” in the Investors section of the
Company’s website at www.aviragentherapeutics.com. An archived
replay of the webcast will be available for 30 days after the live
event concludes.
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of the
next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus upper (HRV)
respiratory infections in moderate-to-severe asthmatics currently
being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor that has received Fast Track designation
by the U.S. FDA, in Phase 2 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit
www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024